Dutch firm awarded €1m credit extension to develop immunotherapy drug

Dutch firm Xenikos has been awarded funding to support the development of T-Guard, which is in clinical phase 1/2 testing for the treatment of steroid-resistant acute graft versus host disease (GVHD). Read more

3 Jan 2017 09:51 Dave Gray News